Brought to you by 
UCB markets Watson's incontinence drug; terminated
08 Jul 2008
Executive Summary
UCB SA's pharmaceutical division UCB Pharma SA has licensed European marketing rights to Watson Pharmaceuticals' Oxytrol, an oxybutynin transdermal system to treat urinary incontinence resulting from overactive bladder.
Deal Industry
- Pharmaceuticals
Deal Status
- Terminated
Deal Type
-
Alliance
- Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
UCB markets Watson's incontinence drug; terminated
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice